Related references
Note: Only part of the references are listed.Comparison of 64Cu-Complexing Bifunctional Chelators for Radioimmunoconjugation: Labeling Efficiency, Specific Activity, and in Vitro/in Vivo Stability
Maggie S. Cooper et al.
BIOCONJUGATE CHEMISTRY (2012)
Development and Characterization of Clinical-Grade 89Zr-Trastuzumab for HER2/neu ImmunoPET Imaging
Eli C. F. Dijkers et al.
JOURNAL OF NUCLEAR MEDICINE (2009)
111In-labeled trastuzumab (herceptin) modified with nuclear localization sequences (NLS):: An Auger electron-emitting radiotherapeutic agent for HER2/neu-amplified breast cancer
Danny L. Costantini et al.
JOURNAL OF NUCLEAR MEDICINE (2007)
Imaging of HER2/neu-positive BT-474 human breast cancer xenografts in athymic mice using In-111-trastuzumab (Herceptin) Fab fragments
Y Tang et al.
NUCLEAR MEDICINE AND BIOLOGY (2005)
Identification of the transmembrane metal binding site in Cu+-transporting PIB-type ATPases
AK Mandal et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2004)
A comparison of the in vitro and in vivo activities of IgG and F(ab′)2 fragments of a mixture of three monoclonal anti-Her-2 antibodies
CI Spiridon et al.
CLINICAL CANCER RESEARCH (2004)
Radiobromination of anti-HER2/neu/ErbB-2 monoclonal antibody using the p-isothiocyanatobenzene derivative of the [76Br]undecahydrobromo-7,8-dicarba-nido-undecaborate(1-) ion
KJ Winberg et al.
NUCLEAR MEDICINE AND BIOLOGY (2004)
Synthesis and evaluation of novel bifunctional chelating agents based on 1,4,7,10-tetraazacyclododecane-N,N′,N,N′-tetraacetic acid for radiolabeling proteins
LL Chappell et al.
NUCLEAR MEDICINE AND BIOLOGY (2003)
Labeling anti-HER2/neu monoclonal antibodies with 111In and 90Y using a bifunctional DTPA chelating agent
MJ Blend et al.
CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS (2003)
Targeting of renal carcinoma with 67/64CU-labeled anti-L1-CAM antibody chCE7:: selection of copper ligands and PET imaging
K Zimmermann et al.
NUCLEAR MEDICINE AND BIOLOGY (2003)
Radiochemical investigations of 177Lu-DOTA-8-Aoc-BBN[7-14]NH2:: an in vitro/in vivo assessment of the targeting ability of this new radiopharmaceutical for PC-3 human prostate cancer cells
CJ Smith et al.
NUCLEAR MEDICINE AND BIOLOGY (2003)
Cross-section measurements of the nuclear reactions Zn-nat(d,x)Cu-64, Zn-66(d,alpha)Cu-64 and Zn-68(p,alpha n)Cu-64 for production of Cu-64 and technical developments for small-scale production of Cu-67 via the Zn-70(p,alpha)Cu-64 process
K Hilgers et al.
APPLIED RADIATION AND ISOTOPES (2003)
Design and synthesis of 225Ac radioimmunopharmaceuticals
MR McDevitt et al.
APPLIED RADIATION AND ISOTOPES (2002)
A new and convenient method for purification of 86Y using a Sr(II) selective resin and comparison of biodistribution of 86Y and 111In labeled Herceptin™
K Garmestani et al.
NUCLEAR MEDICINE AND BIOLOGY (2002)
Anti-human epidermal growth factor receptor 2 monoclonal antibody therapy for breast cancer
DS Leonard et al.
BRITISH JOURNAL OF SURGERY (2002)
Conjugation of monoclonal antibodies with TETA using activated esters:: Biological comparison of 64Cu-TETA-1A3 with 64Cu-BAT-2IT-1A3
MR Lewis et al.
CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS (2001)
Assessment of methods for tissue-based detection of the HER-2/neu alteration in human breast cancer:: A direct comparison of fluorescence in situ hybridization and immunohistochemistry
G Pauletti et al.
JOURNAL OF CLINICAL ONCOLOGY (2000)
Recombinant anti-human HER2/neu IgG3-(GM-CSF) fusion protein retains antigen specificity and cytokine function and demonstrates antitumor activity
JS Dela Cruz et al.
JOURNAL OF IMMUNOLOGY (2000)
In vivo transchelation of copper-64 from TETA-octreotide to superoxide dismutase in rat liver
LA Bass et al.
BIOCONJUGATE CHEMISTRY (2000)
Synthesis, characterization, and evaluation of a novel bifunctional chelating agent for the lead isotopes Pb-203 and Pb-212
LL Chappell et al.
NUCLEAR MEDICINE AND BIOLOGY (2000)
Share Paper
